연속 바이오프로세스 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Continuous Bioprocessing Market Growth & Trends:

The global continuous bioprocessing market size is anticipated to reach USD 911.43 million by 2030, growing at a CAGR of 18.63% from 2025 to 2030, according to a new report by Grand View Research, Inc. The continuous bioprocessing market is driven by the increasing demand for biologics, biosimilars, and advanced therapies such as cell and gene therapies and monoclonal antibodies (mAbs). As pharmaceutical and biotechnology companies seek higher efficiency, reduced costs, and faster production cycles, continuous bioprocessing has emerged as a key solution. Compared to traditional batch processing, continuous bioprocessing offers higher productivity, better scalability, and improved process control, making it essential for large-scale biologics manufacturing. Additionally, advancements in single-use bioreactors, perfusion-based systems, and process analytical technologies (PAT) are accelerating the adoption of continuous bioprocessing across the industry.

The COVID-19 pandemic acted as a major catalyst for the adoption of continuous bioprocessing, as the need for rapid vaccine production, scalable manufacturing, and efficient supply chains intensified. Companies developing mRNA vaccines, monoclonal antibodies, and antiviral therapies turned to continuous bioprocessing to meet global demand while maintaining high product quality. The pandemic also highlighted vulnerabilities in traditional batch processing, leading to increased investments in flexible, scalable, and automated continuous biomanufacturing solutions. As a result, post-pandemic, many biopharma companies have continued to invest in continuous bioprocessing technologies, ensuring long-term market growth and resilience in global biomanufacturing.

The increasing collaboration between biopharma companies, CMOs, and regulatory agencies is also driving market growth. Regulatory bodies such as the FDA and EMA have been actively supporting the shift towards continuous manufacturing by providing guidelines, incentives, and faster approval pathways. Moreover, key players are investing heavily in automation, AI-driven process monitoring, and real-time analytics, further optimizing production workflows. The integration of continuous chromatography, inline quality control, and modular bioreactor systems is streamlining biologics manufacturing, reducing variability, and ensuring consistent product quality.

Continuous Bioprocessing Market Report Highlights:

• Based on product, consumables & reagents dominated the market in 2024. The shift from traditional batch processing to continuous bioprocessing has led to a growing demand for continuous bioprocessing consumables& reagents
• Based on application, the monoclonal antibodies segment dominated the market, with the largest revenue share of 29.98% in 2024. The shift toward biosimilars and regulatory support for process intensification further fuel adoption, as manufacturers seek to reduce production costs while maintaining high product purity and potency
• Based on end use, pharmaceutical and biotechnology companies dominated the market, with the largest revenue share of 48.43% in 2024. The regulatory support from agencies like the FDA and EMA for continuous manufacturing and process intensification is further encouraging biopharma firms to invest in next-generation bioprocessing solutions
• In 2024, North America led the market, accounting for the largest revenue share of 37.46%. This dominance is fueled by significant investments in biopharmaceutical R&D, a well-established manufacturing infrastructure, and favorable regulatory policies supporting advanced bioprocessing technologies.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Product
  • 1.1.2. Application
  • 1.1.3. End Use
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives
  • 1.9.1. Objective 1
  • 1.9.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Continuous bioprocessing market Variables and Trends

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Drivers
    • 3.2.1.1. Growing Demand for Biologics & Biosimilars
    • 3.2.1.2. Technological Advancements & Single-Use Systems
  • 3.2.2. Restraints
    • 3.2.2.1. High Initial Investment & Process Complexity
• 3.3. Industry Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Continuous Bioprocessing: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. Continuous bioprocessing market: Product Movement Analysis
• 4.3. Continuous bioprocessing market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Instruments
  • 4.4.1. Instruments market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.2. Bioreactors
    • 4.4.2.1. Bioreactors market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.3. Filtration Systems
    • 4.4.3.1. Filtration systems market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.4. Chromatography Systems
    • 4.4.4.1. Chromatography systems market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.5. Process Analytical Technologies
    • 4.4.5.1. Process analytical technologies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.6. Others
    • 4.4.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Consumables & Reagents
  • 4.5.1. Consumables & reagents market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5.2. Media & Buffers
    • 4.5.2.1. Media & buffers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5.3. Filters & Membranes
    • 4.5.3.1. Filters & membranes market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5.4. Resin
    • 4.5.4.1. Resin market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5.5. Tubing & Bags
    • 4.5.5.1. Tubing & bags market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5.6. Other
    • 4.5.6.1. Other market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Continuous Bioprocessing: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. Continuous bioprocessing market: Application Movement Analysis
• 5.3. Continuous bioprocessing market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Monoclonal antibodies
  • 5.4.1. Monoclonal antibodies market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Vaccines
  • 5.5.1. Vaccines market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.6. Cell and gene therapy
  • 5.6.1. Cell and gene therapy market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.7. Research & Development
  • 5.7.1. Research & development market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.8. Other Applications
  • 5.8.1. Other applications market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Continuous Bioprocessing: End Use Estimates & Trend Analysis

• 6.1. End Use Segment Dashboard
• 6.2. Continuous bioprocessing market: End Use Movement Analysis
• 6.3. Continuous bioprocessing market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Pharmaceutical & Biotechnology Companies
  • 6.4.1. Pharmaceutical and biotechnology companies market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. CMOs and CROs
  • 6.5.1. CMOs and CROs market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Research and Academic Institutes
  • 6.6.1. Research and academic institutes market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Continuous Bioprocessing: Regional Estimates & Trend Analysis

• 7.1. Regional Market Dashboard
• 7.2. Regional Market Share Analysis, 2024 & 2030
• 7.3. Continuous bioprocessing market by Region: Key Takeaways
• 7.4. North America
  • 7.4.1. North America market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. U.S. market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Canada market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Mexico market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.5. Europe
  • 7.5.1. Europe market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. UK market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Germany market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. France market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Italy market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Spain market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.7. Sweden
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Sweden market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.8. Norway
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Norway market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.9. Denmark
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Denmark market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Japan market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. China market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. India market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Australia market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6.6. Thailand
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Thailand market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6.7. South Korea
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. South Korea market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Brazil market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Argentina market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.8. MEA
  • 7.8.1. MEA market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Saudi Arabia market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.8.3. South Africa
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. South Africa market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. UAE market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Kuwait market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Categorization
• 8.2. Company Market Position Analysis, 2024
• 8.3. Participant Overview
  • 8.3.1. Danaher
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Product benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. Sartorius AG
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Product benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Thermo Fisher Scientific Inc.
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Product benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. WuXi Biologics
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Ginkgo Bioworks
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Merck KGaA
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. GE Healthcare
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Repligen Corporation
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Asahi Kasei Bioprocess America, Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives